Pieris Pharmaceuticals (NASDAQ:PIRS) and The Competition Head-To-Head Review

Pieris Pharmaceuticals (NASDAQ: PIRS) is one of 286 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its rivals? We will compare Pieris Pharmaceuticals to related businesses based on the strength of its analyst recommendations, valuation, profitability, dividends, institutional ownership, earnings and risk.

Valuation and Earnings

This table compares Pieris Pharmaceuticals and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Pieris Pharmaceuticals $5.83 million -$22.79 million -10.20
Pieris Pharmaceuticals Competitors $284.49 million $34.10 million 64.83

Pieris Pharmaceuticals’ rivals have higher revenue and earnings than Pieris Pharmaceuticals. Pieris Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Pieris Pharmaceuticals has a beta of 1.79, indicating that its share price is 79% more volatile than the S&P 500. Comparatively, Pieris Pharmaceuticals’ rivals have a beta of 5.97, indicating that their average share price is 497% more volatile than the S&P 500.

Insider & Institutional Ownership

50.5% of Pieris Pharmaceuticals shares are owned by institutional investors. Comparatively, 49.7% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 4.1% of Pieris Pharmaceuticals shares are owned by company insiders. Comparatively, 17.5% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.


This table compares Pieris Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pieris Pharmaceuticals -321.83% -221.93% -42.02%
Pieris Pharmaceuticals Competitors -5,229.27% -213.46% -38.10%

Analyst Recommendations

This is a summary of recent ratings and price targets for Pieris Pharmaceuticals and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pieris Pharmaceuticals 0 0 3 0 3.00
Pieris Pharmaceuticals Competitors 893 3287 11783 235 2.70

Pieris Pharmaceuticals currently has a consensus price target of $9.00, suggesting a potential upside of 19.21%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.32%. Given Pieris Pharmaceuticals’ rivals higher probable upside, analysts plainly believe Pieris Pharmaceuticals has less favorable growth aspects than its rivals.


Pieris Pharmaceuticals rivals beat Pieris Pharmaceuticals on 9 of the 13 factors compared.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company’s second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate.

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply